Related Experiment Video
Updated: Nov 16, 2025
Highlighting and Reducing the Impact of Negative Aging Stereotypes During Older Adults' Cognitive Testing
Published on: January 24, 2020
Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis
Sarah F Ackley1, Scott C Zimmerman1, Willa D Brenowitz1,2
1Department of Epidemiology and Biostatistics, University of California, San Francisco, 550 16th Street, San Francisco, CA, USA.
Objective:
To evaluate trials of drugs that target amyloid to determine whether reductions in amyloid levels are likely to improve cognition.
Design:
Instrumental variable meta-analysis.
Setting:
14 randomized controlled trials of drugs for the prevention or treatment of Alzheimer's disease that targeted an amyloid mechanism, identified from ClinicalTrials.gov.
Population:
Adults enrolled in randomized controlled trials of amyloid targeting drugs. Inclusion criteria for trials vary, but typically include adults aged 50 years or older with a diagnosis of mild cognitive impairment or Alzheimer's disease, and amyloid positivity at baseline.
Main Outcome Measures:
Analyses included trials for which information could be obtained on both change in brain amyloid levels measured with amyloid positron emission tomography and change in at least one cognitive test score reported for each randomization arm.
Results:
Pooled results from the 14 randomized controlled trials were more precise than estimates from any single trial. The pooled estimate for the effect of reducing amyloid levels by 0.1 standardized uptake value ratio units was an improvement in the mini-mental state examination score of 0.03 (95% confidence interval -0.06 to 0.1) points. This study provides a web application that allows for the re-estimation of the results when new data become available and illustrates the magnitude of the new evidence that would be necessary to achieve a pooled estimate supporting the benefit of reducing amyloid levels.
Conclusions:
Pooled evidence from available trials reporting both reduction in amyloid levels and change in cognition suggests that amyloid reduction strategies do not substantially improve cognition.
Insights
This study evaluated amyloid-targeting drugs for Alzheimer's disease. Results suggest that reducing amyloid levels does not significantly improve cognitive function in patients.
Area of Science:
- Neuroscience
- Pharmacology
- Clinical Trials
Background:
- Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by the accumulation of amyloid plaques in the brain.
- Amyloid-targeting therapies aim to reduce amyloid burden, hypothesizing this will slow or reverse cognitive decline.
- Current evidence on the efficacy of amyloid reduction for cognitive improvement in AD is inconclusive.
Purpose of the Study:
- To evaluate clinical trials investigating drugs targeting amyloid for Alzheimer's disease.
- To determine if reductions in amyloid levels correlate with improvements in cognitive function.
- To provide a meta-analysis of existing data to assess the therapeutic benefit of amyloid reduction.
Main Methods:
- An instrumental variable meta-analysis was conducted.
- Data were pooled from 14 randomized controlled trials (RCTs) of amyloid-targeting drugs for AD.
- Included trials measured changes in brain amyloid levels (via positron emission tomography) and cognitive test scores.
Main Results:
- Pooled analysis of 14 RCTs provided more precise estimates than individual trials.
- A reduction of 0.1 standardized uptake value ratio units in amyloid levels was associated with a 0.03-point increase in Mini-Mental State Examination scores (95% CI: -0.06 to 0.1).
- A web application was developed for re-estimating results with new data.
Conclusions:
- Pooled evidence indicates that amyloid reduction strategies do not substantially improve cognition in Alzheimer's disease patients.
- The findings suggest that targeting amyloid alone may not be sufficient for meaningful cognitive benefit.
- Further research is needed to explore alternative or combination therapeutic approaches.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
01:26Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists